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Abstract
© 2015 Stichting European Society for Clinical Investigation Journal Foundation. Background:
Plasmacytoid dendritic cells (pDCs) are multifunctional bone-marrow-derived immune cells that
are key players  in  bridging the innate and adaptive immune systems.  Activation of  pDCs
through toll-like receptor agonists has proven to be an effective treatment for some neoplastic
disorders.  Materials  and  methods:  In  this  mini-review,  we  will  explore  the  fascinating
contribution of pDCs to neoplastic pathology and discuss their potential utilization in cancer
immunotherapy. Results: Current research suggests that pDCs have cytotoxic potential and can
effectively induce apoptosis of tumour-derived cells lines. They are also reported to display
tolerogenic function with the ability to suppress T-cell proliferation, analogous to regulatory T
cells. In this capacity, they are critical in the suppression of autoimmunity but can be exploited
by  tumour  cells  to  circumvent  the  expansion  of  tumour-specific  T  cells,  thereby  allowing
tumours to persist. Conclusion: Several forms of skin cancer are successfully treated with the
topical  drug  Imiquimod,  which  activates  pDCs  through  toll-like  receptor  7  engagement.
Additionally, pDC-based anticancer vaccines have shown encouraging results for the treatment
of melanoma in early trials. Future studies regarding the contributions of pDCs to malignancy
will likely afford many opportunities for immunotherapy strategies.
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